Literature DB >> 34159722

Expansion of the clinical phenotype of GALE deficiency.

Rebecca Markovitz1,2, Nichole Owen2,3, Lisa Forbes Satter4,5,6, Susan Kirk6,7,8, Donald H Mahoney6,7,8, Alison A Bertuch2,6,7,8, Fernando Scaglia2,6,9.   

Abstract

Congenital disorders of glycosylation are a group of rare monogenic inborn errors of metabolism caused by defective glycoprotein and glycolipid glycan synthesis and attachment. Here, we present a patient with galactose epimerase deficiency, also known as GALE deficiency, accompanied by pancytopenia and immune dysregulation. She was first identified by an abnormal newborn screen for galactosemia with subsequent genetic evaluation due to pancytopenia and immune dysregulation. The evaluation ultimately revealed that her known diagnosis of GALE deficiency was the cause of her hematologic and immune abnormalities. These findings further expand the clinical spectrum of disease of congenital disorders of glycosylation.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  B-cell deficiency; congenital disorders of glycosylation; dysmegakaryopoiesis; glycosylation; immune dysfunction; thrombocytopenia

Mesh:

Substances:

Year:  2021        PMID: 34159722     DOI: 10.1002/ajmg.a.62384

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  2 in total

1.  Transient Cytopenias as a Rare Presentation of Classic Galactosemia.

Authors:  Maria Gianniki; Irini Nikaina; Georgia Avgerinou; Christina Kanaka-Gantenbein; Tania Siahanidou
Journal:  Cureus       Date:  2022-03-12

2.  Galactose epimerase deficiency: lessons from the GalNet registry.

Authors:  Britt Derks; Gerard T Berry; M Estela Rubio-Gozalbo; Didem Demirbas; Rodrigo R Arantes; Samantha Banford; Alberto B Burlina; Analía Cabrera; Ana Chiesa; M Luz Couce; Carlo Dionisi-Vici; Matthias Gautschi; Stephanie Grünewald; Eva Morava; Dorothea Möslinger; Sabine Scholl-Bürgi; Anastasia Skouma; Karolina M Stepien; David J Timson
Journal:  Orphanet J Rare Dis       Date:  2022-09-02       Impact factor: 4.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.